

GLP-1 Pipeline Update: May 2026

As the GLP-1 pipeline continues to grow, Prime Therapeutics actively monitors this emerging landscape and provides a credible clinical snapshot of what is on the horizon. The below table displays the earliest potential approval dates of the agents listed. Dates are based on manufacturer-published announcements or communications, or are estimated based on study completion dates, and may change as more information becomes available.

Drug / dosage form	Diabetes & diabetes-related conditions			Obesity or overweight & related conditions							Other
	T2DM	T2DM + CVD	Diabetic nephropathy	Obesity or overweight	Obesity or overweight + CVD	CLBP + obesity or overweight	HTN + obesity or overweight	OSA + obesity or overweight	OA of knee + obesity or overweight	T1DM ± obesity or overweight	MASH
Amgen											
maridebart cafraglutide / SC				2028							
AstraZeneca											
exenatide (Bydureon BCise) / SC	FDA approved (ages ≥10 years)										
Eli Lilly											
dulaglutide (Trulicity) / SC	FDA approved (ages ≥10 years)	FDA approved									
tirzepatide (Mounjaro) / SC	FDA approved (ages ≥10 years)	FDA decision mid-2026								2028	
tirzepatide (Zepbound) / SC				FDA approved				FDA approved			
orforglipron (Foundayo) / oral	2026			FDA approved			2028	2027			
retatrutide / SC	2027			2027	2027	2028		2027	2027		

	Diabetes & diabetes-related conditions			Obesity or overweight & related conditions							Other
Drug / dosage form	T2DM	T2DM + CVD	Diabetic nephropathy	Obesity or overweight	Obesity or overweight + CVD	CLBP + obesity or overweight	HTN + obesity or overweight	OSA + obesity or overweight	OA of knee + obesity or overweight	T1DM ± obesity or overweight	MASH
Novo Nordisk											
liraglutide (Victoza)* / SC	FDA approved (ages ≥10 years)	FDA approved		2028							
liraglutide (Saxenda) / SC				FDA approved (ages ≥12 years)							
liraglutide + insulin degludec (Xultophy) / SC	FDA approved										
semaglutide (Ozempic) 1.5 mg, 4 mg & 9 mg / oral	FDA approved	FDA approved									
semaglutide (Rybelsus) 3 mg, 7 mg & 14 mg / oral	FDA approved	FDA approved									
semaglutide 25 mg (Ozempic) / oral	<i>FDA decision Q4 2026</i>										
semaglutide 25 mg (Wegovy) / oral				FDA approved	FDA approved						
semaglutide 1 mg & 2 mg (Ozempic) / SC	FDA approved	FDA approved	FDA approved								
semaglutide 1.7 mg & 2.4 mg (Wegovy) / SC				FDA approved (ages ≥12 years)	FDA approved						FDA approved

	Diabetes & diabetes-related conditions			Obesity or overweight & related conditions							Other
Drug / dosage form	T2DM	T2DM + CVD	Diabetic nephropathy	Obesity or overweight	Obesity or overweight + CVD	CLBP + obesity or overweight	HTN + obesity or overweight	OSA + obesity or overweight	OA of knee + obesity or overweight	T1DM ± obesity or overweight	MASH
semaglutide 7.2 mg (Wegovy HD) / SC				FDA approved							
cagrilintide + semaglutide / SC	2027			FDA decision December 2026							
Sanofi											
lixisenatide + insulin glargine (Soliqua) / SC	FDA approved										
Viking											
VK2735 / SC				2028							
Zealand, Boehringer Ingelheim											
survodutide / SC				2027	2027						2027 (+ obesity)

*Generics available

Glossary

CLBP = chronic low back pain

CVD = cardiovascular disease

FDA = Food and Drug Administration

GLP-1 = glucagon-like peptide-1 receptor agonist

HTN = hypertension

MASH = metabolic dysfunction-associated steatohepatitis

OA = osteoarthritis

OSA = obstructive sleep apnea

SC = subcutaneous

T1DM = type 1 diabetes mellitus

Disclaimer

The drug pipeline is fluid; the dates and information within this publication are subject to change. Nothing herein is or shall be construed as a promise or representation regarding past or future events and Prime Therapeutics expressly disclaims any and all liability relating to the use of or reliance on the information contained in this presentation. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to or disclosed to others at any time without the prior written consent of Prime Therapeutics.

All brand names are property of their respective owners.